SI-B036 clinical trials
How each study uses SI-B036 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SI-B036 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SI-B036
- 7
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Sichuan Baili Pharmaceutical Co., Ltd. (6) · SystImmune Inc. (1)
Studies
Open first, then newest update. How each study uses SI-B036 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- SI-B036-ST-101 in Advanced/Metastatic Solid TumorsRecruitingPhase 1SystImmune Inc.NCT07857616Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07763639Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07753226Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07678970Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsNot yet recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07744243Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid TumorsNot yet recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07778862Written as SI-B036
- A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07606612Written as SI-B036